What top creators are saying about Ginkgo Bioworks Holdings, Inc.(DNA)

The speaker briefly called the stock a good short but provided no supporting valuation analysis, catalyst, or risk discussion.

The speaker explicitly called DNA a good short near $10, but offered no supporting valuation analysis or catalyst.

The host called it a good short and disparaged it as a penny stock, but provided no supporting company-specific analysis.

Mentioned as a possible short candidate; the speaker was particularly negative and called it a poor-quality company, but gave no detailed short thesis or price target.

Suggested as a possible short and described in strongly negative terms, but no detailed financial or operating evidence was provided.

The speaker called the company overvalued and a major short, citing a sharp share-price rise without news; he said he had shorted and then covered the position.

A speaker was skeptical of the AI-biotech narrative and questioned whether AI association matters without successful drug-development results. The speaker’s short position was described inconsistently.

The ticker appeared in the episode title, but there was no substantive company-specific discussion.

The host criticized the AI-biotechnology rally and said he had exited a short position after a volatile move; he later noted a sharp intraday decline.

The host described the company as dramatically overvalued and a poor business, while noting that its shares had risen sharply without clear news due to momentum.

The speaker called the stock a significant short opportunity but provided no supporting rationale, price target, or timeline.

Mentioned in connection with testing AI-driven lab automation, but no product results, financial performance, commercial traction, or recommendation were discussed.

Ginkgo Bioworks was mentioned as a company that would test AI-related tools; no commercial results or financial details were discussed.

The speaker called the company poor quality and said it could be a good short, but provided no specific catalyst or supporting analysis.

Mentioned without substantive investment commentary.

Experienced a 98% drawdown from peak, demonstrating high execution risk in non-commercialized biotech.

Longevity-focused biotech is viewed as a bad investment driven by irrational health-seeking buyers rather than returns.

Identified as a player in the AI-driven drug discovery and robotic lab space, utilizing automated systems to shorten R&D cycles.

Identified as a 'picks and shovels' play providing hardware and software for the synthetic biology ecosystem as the sector moves toward industrial-scale application.

Operates in the directed evolution and microbial editing space, positioned to benefit from breakthroughs in enzyme engineering and environmental bioremediation.

The partnership with OpenAI is a powerful validation of Ginkgo's platform, positioning them as a key infrastructure player for AI-driven scientific discovery, with significant growth potential in the health and wellness market.

Its partnership with OpenAI to automate protein synthesis is highlighted as the 'future of science factories,' positioning the company at the forefront of the AI and Biotech growth trend.

Their partnership with OpenAI to create 'science factories' that automate biological research is highlighted as the 'future of science,' representing a powerful convergence of AI and biotech.